Sirna Issued Australian Patent on Expressed RNAi Against Huntington's Gene

Sirna Therapeutics reported this week that the Australian patent office has granted the company a patent covering expressed siRNAs targeting the Huntington's disease gene.

According to the company, this is the first patent granted anywhere in the world covering vector-expressed siRNAs against a disease gene. The patent claims, Sirna added, are not limited to a specific siRNA sequence or structure and broadly cover any vector expressed siRNA used against the HD gene.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.